NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, News, & Analysis

$20.43
-0.04 (-0.20 %)
(As of 06/27/2019 04:24 AM ET)
Today's Range
$20.19
Now: $20.43
$20.6150
50-Day Range
$18.85
MA: $20.71
$22.73
52-Week Range
$15.04
Now: $20.43
$25.43
Volume131,094 shs
Average Volume184,757 shs
Market Capitalization$961.54 million
P/E Ratio97.29
Dividend YieldN/A
Beta1.4
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$294.67 million
Cash Flow$0.59 per share
Book Value$7.90 per share

Profitability

Net Income$-5,740,000.00

Miscellaneous

Employees2,078
Market Cap$961.54 million
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable

Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How will Amphastar Pharmaceuticals' stock buyback program work?

Amphastar Pharmaceuticals announced that its board has approved a share repurchase plan on Thursday, August 10th 2017, which authorizes the company to repurchase $20,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its stock is undervalued.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) posted its earnings results on Thursday, May, 9th. The company reported $0.10 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.03 by $0.07. The firm earned $79.79 million during the quarter, compared to analyst estimates of $76.21 million. Amphastar Pharmaceuticals had a return on equity of 5.14% and a net margin of 0.74%. The company's revenue for the quarter was up 36.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Amphastar Pharmaceuticals.

What price target have analysts set for AMPH?

4 equities research analysts have issued 12-month price targets for Amphastar Pharmaceuticals' stock. Their predictions range from $22.20 to $29.00. On average, they anticipate Amphastar Pharmaceuticals' share price to reach $25.05 in the next year. This suggests a possible upside of 22.6% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals.

What is the consensus analysts' recommendation for Amphastar Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amphastar Pharmaceuticals.

Has Amphastar Pharmaceuticals been receiving favorable news coverage?

News stories about AMPH stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Amphastar Pharmaceuticals.

Are investors shorting Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals saw a decrease in short interest in June. As of June 15th, there was short interest totalling 1,239,000 shares, a decrease of 8.7% from the May 15th total of 1,356,900 shares. Based on an average daily volume of 166,000 shares, the days-to-cover ratio is presently 7.5 days. Currently, 3.6% of the company's shares are short sold. View Amphastar Pharmaceuticals' Current Options Chain.

Who are some of Amphastar Pharmaceuticals' key competitors?

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Clovis Oncology (CLVS), Neurocrine Biosciences (NBIX), Sarepta Therapeutics (SRPT), bluebird bio (BLUE) and BioMarin Pharmaceutical (BMRN).

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the folowing people:
  • Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 69)
  • Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 72)
  • Mr. Jason B. Shandell, Pres, Gen. Counsel & Director (Age 45)
  • Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 51)
  • Mr. Jacob Liawatidewi M.B.A., Sr. VP of Corp. Admin. Center, Sales and Marketing & Corp. Sec. (Age 45)

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (3.13%), Rothschild & Co. Asset Management US Inc. (0.67%), Nordea Investment Management AB (0.54%), Martingale Asset Management L P (0.47%), Argent Capital Management LLC (0.45%) and Rhumbline Advisers (0.23%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, Stephen B Shohet, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

Which institutional investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including Argent Capital Management LLC, Rothschild & Co. Asset Management US Inc., Boston Advisors LLC, American International Group Inc., Zurcher Kantonalbank Zurich Cantonalbank and Quantamental Technologies LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Howard Lee, Jack Y Zhang, Jason B Shandell, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Which institutional investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Alambic Investment Management L.P., Sawgrass Asset Management LLC, California Public Employees Retirement System, Tibra Equities Europe Ltd, Public Employees Retirement Association of Colorado, Nisa Investment Advisors LLC and State Board of Administration of Florida Retirement System. View Insider Buying and Selling for Amphastar Pharmaceuticals.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $20.43.

How big of a company is Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals has a market capitalization of $961.54 million and generates $294.67 million in revenue each year. The company earns $-5,740,000.00 in net income (profit) each year or $0.21 on an earnings per share basis. Amphastar Pharmaceuticals employs 2,078 workers across the globe.View Additional Information About Amphastar Pharmaceuticals.

What is Amphastar Pharmaceuticals' official website?

The official website for Amphastar Pharmaceuticals is http://www.amphastar.com/.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]


MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  289 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  515
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/27/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel